Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 11 - 03 tags : Preclinical save search
Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting
Published: 2022-11-03 (Crawled : 14:00) - globenewswire.com
BMEA | $10.765 -1.96% 340K
|
Professional, Scientific, and T...
|
| O: -2.65%
H: 10.08%
C: 5.36%
bmf-500 preclinical meeting
Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022
Published: 2022-11-03 (Crawled : 14:00) - globenewswire.com
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: -1.53%
H: 3.8%
C: 1.69%
ongoing nephropathy trials research preclinical kidney week therapeutics igan
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
BEAM | $22.99 -2.05% 410K
|
Health Technology
|
| O: -2.27%
H: 6.76%
C: 3.29%
disease preclinical meeting therapeutics
Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
SANA | $8.48 4.82% 630K
|
|
| O: -3.44%
H: 3.39%
C: -10.87%
preclinical meeting
Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
AFMD | $4.95 -7.48% 51K
|
Health Technology
|
| O: 11.24%
H: 15.69%
C: -1.6%
afm13 preclinical meeting afm28 presentation phase 1
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
FATE | News | $4.21 -7.27% 1.2M
|
Health Technology
|
| O: -1.65%
H: 3.2%
C: -1.32%
preclinical meeting therapeutics platform
ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
ORIC | $8.275 -5.64% 160K
|
Health Technology
|
| O: -2.62%
H: 1.92%
C: -3.46%
cd73 pharmaceuticals preclinical meeting program
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.85 51.79% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
MULN | News | $3.805 39.38% 11M
|
Information
RILY | $30.01 38.17% 11M
|
Finance
MTC | $3.04 35.71% 6.7M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.